NCT06437678View on ClinicalTrials.gov

Phase II Study of Liposomal Irinotecan for Advanced Refractory Gastric Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 27, 2024

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2026

Conditions
Gastric Cancer
Interventions
DRUG

Liposomal Irinotecan Hydrochloride

Liposomal Irinotecan Hydrochloride Injection (Ⅱ) 56.5mg/m2 every 2 weeks

Trial Locations (1)

Unknown

Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou

All Listed Sponsors
lead

Zhejiang Cancer Hospital

OTHER

NCT06437678 - Phase II Study of Liposomal Irinotecan for Advanced Refractory Gastric Cancer | Biotech Hunter | Biotech Hunter